Tirzepatide
LY3298176
Tirzepatide is a single modified peptide that activates GIP and GLP-1 receptors. Dual receptor activity does not mean it is a blend of two compounds.
Reviewed September 2026
- Residues
- 39. verified: 39 main-chain residues, including both Aib residues; lipid/linker moieties are excluded from chain length and included in molecular mass.
- Average mass
- 4,813.53 Da. verified: Sponsor-label molecular weight for tirzepatide, C225H348N48O68, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement.
- pI
- Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.
Reference details
| Residues | 39 |
|---|---|
| Average mass | 4,813.53 Da |
| pI | Not established |
| Aliases | LY3298176 |
|---|---|
| Research area | Metabolic |
Property basis and sources
These describe the reference compound or formulation, not identification or testing of the supplied lot.
Tirzepatide: Aib at positions 2 and 13, C-terminal amide, and Lys20-linked C20 diacid/linker; full modified reference peptide, excluding formulation excipients. Reference only, not a sold-lot measurement.
- Residues: 39 (verified). 39 main-chain residues, including both Aib residues; lipid/linker moieties are excluded from chain length and included in molecular mass. Residues source 1 Residues source 2 Residues source 3
- Average mass: 4,813.53 Da (verified). Sponsor-label molecular weight for tirzepatide, C225H348N48O68, including its covalent modifications. Average molecular mass, not monoisotopic mass. Excludes unlisted counterions and formulation excipients; not an Aminos lot measurement. Average mass source 1 Average mass source 2
- pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1
Reference scope and linked records
Reference type: Modified peptide.
This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.
Catalogue context: Tirzepatide. The product retains its own name and specification; this link does not certify equivalence to published study material.
Related references
Sources and their scope
- LY3298176: from discovery to clinical proof of concept. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.
About Tirzepatide
Identity and context
The discovery designation is LY3298176. The original investigators describe a fatty-acid-modified peptide and assess both incretin receptors. Tirzepatide is a distinct chemical identity from semaglutide and from the triple-receptor agonist retatrutide; these names are not interchangeable.
Reference classification
Modified peptide. The linked catalogue product is Tirzepatide. This reference does not independently authenticate the material supplied.
Storage and handling
Analytical specification
Compare the full modified structure and analytical identifier with the specification. Confirm salt, water content and the basis of the reported amount separately from receptor identity.
Storage and experimental handling
Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.
Research evidence
| Area | Summary | Evidence |
|---|---|---|
| What the source examines | Coskun and colleagues combined receptor assays, mouse experiments and an early randomized human study. They reported activity through both receptors and measured metabolic and pharmacokinetic outcomes. Gastrointestinal adverse events were among the reported findings. The paper provides discovery and early proof-of-concept evidence rather than a specification for a retail preparation. | Source context |
| What cannot be inferred | Human results belong to the characterized investigational material and study population. They cannot establish equivalence, clinical performance or safety of the catalogue product. No dosing or administration instructions are provided here. | Evidence limits |
References
Sources used for the data on this page, checked September 2026.
- LY3298176: from discovery to clinical proof of conceptPrimary source for the reference discussion; not lot-specific product evidence.
Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.